- Home
- REE vs CING Comparison
REE vs CING Comparison
Compare REE & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- CING
- Stock Information
- Founded
- REE 2011
- CING 2012
- Country
- REE Israel
- CING United States
- Employees
- REE N/A
- CING N/A
- Industry
- REE Auto Manufacturing
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- CING Health Care
- Exchange
- REE Nasdaq
- CING Nasdaq
- Market Cap
- REE 22.4M
- CING 22.9M
- IPO Year
- REE N/A
- CING 2021
- Fundamental
- Price
- REE N/A
- CING N/A
- Analyst Decision
- REE Strong Buy
- CING Strong Buy
- Analyst Count
- REE 2
- CING 4
- Target Price
- REE $11.75
- CING $31.00
- AVG Volume (30 Days)
- REE 135.6K
- CING 160.4K
- Earning Date
- REE 09-16-2025
- CING 11-06-2025
- Dividend Yield
- REE N/A
- CING N/A
- EPS Growth
- REE N/A
- CING N/A
- EPS
- REE N/A
- CING N/A
- Revenue
- REE $183,000.00
- CING N/A
- Revenue This Year
- REE $6,661.20
- CING N/A
- Revenue Next Year
- REE $2,240.01
- CING N/A
- P/E Ratio
- REE N/A
- CING N/A
- Revenue Growth
- REE N/A
- CING N/A
- 52 Week Low
- REE $0.53
- CING $3.02
- 52 Week High
- REE $11.72
- CING $6.01
- Technical
- Relative Strength Index (RSI)
- REE 57.71
- CING 53.04
- Support Level
- REE $0.68
- CING $3.91
- Resistance Level
- REE $0.84
- CING $4.24
- Average True Range (ATR)
- REE 0.07
- CING 0.21
- MACD
- REE 0.00
- CING 0.06
- Stochastic Oscillator
- REE 57.00
- CING 79.18
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.